Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Междисциплинарный подход – залог успеха лечения пациентов с иммуновоспалительными заболеваниями. Клинический случай
________________________________________________
Kagramanova AV, Knyazev OV, Kulakov DS, Vinnitskaya EV, Sandler IuG, Savenkova NA, Lukina GV, Parfenov AI. Interdisciplinary approach is a key of efficient treatment in patients with immunoinflammatory diseases. Case report. Consilium Medicum. 2021; 23 (5): 440–443. DOI: 10.26442/20751753.2021.5.200821
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: болезнь Крона, воспалительные заболевания кишечника, внекишечные проявления
________________________________________________
The article is devoted to clinical case of concomitant immune-inflammatory diseases: Crohn disease, ankylosing spondylitis, primary sclerosing cholangitis. Chronic immunoinflammatory diseases (CID) caused disability, characterized by similar genetic and immunological factors. The emergence of genetically engineered biological drugs has changed the prognosis for both musculo-skeletal diseases and inflammatory bowel disease (IBD). The intersection of the therapeutic spectrum in CID is a very important point in choosing the tactics of management of patients with these pathologies. This clinical case demonstrates the importance of early diagnosis of immunoinflammatory diseases and application of genetically engineered biological drugs, that contributes to prevention disability and enhancement of quality of life of IBD patients. It is concluded that treatment of immunoinflammatory diseases should be carried out taking into account the course of the IBD and the multidisciplinary approach, which requires close cooperation of doctors of various specialties.
Keywords: Crohn’s disease, inflammatory bowel disease, extraintestinal manifestations
2. Парфенов А.И. Энтерология: руководство для врачей. М.: Медицинское информационное агентство, 2009 [Parfenov AI. Enterology: a guide for doctors. Moscow: Medical news agency, 2009 (in Russian)].
3. Geng X, Biancone L, Dai HH, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114:912-22. DOI:10.1016/s0016-5085(98)70310-5
4. Biancone L, Mandal A, Yang H, et al. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology. 1995;109:3-12. DOI:10.1016/0016-5085(95)90263-5
5. Van Sommeren S, Janse M, Karjalainen J, et al. Extraintestinal manifestations and complications in inflammatory bowel disease: From shared genetics to shared biological pathways. Inflamm Bowel Dis. 2014;20:987-94. DOI:10.1097/MIB.0000000000000032
6. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227-36. DOI:10.3748/wjg.v11.i46.7227
7. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:307-27. DOI:10.1016/s0889-8553(01)00019-x
8. Mendes FD, Levy C, Enders FB, et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007;102:344-50. DOI:10.1111/j.1572-0241.2006.00947.x
9. Хатьков И.Е., Парфенов А.И., Князев О.В., и др. Воспалительные заболевания в практике терапевта и хирурга. М., 2017; с. 70–2 [Khat,kov IE, Parfenov AI, Kniazev OV, et al. Inflammatory diseases in the practice of a therapist and surgeon. Moscow, 2017; p. 70–2 (in Russian)].
________________________________________________
1. Hedin CRH, Vavricka SR, Stagg AJ, et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohn’s Colitis. 2019;13(5):541-54. DOI:10.1093/ecco-jcc/jjy191
2. Parfenov AI. Enterology: a guide for doctors. Moscow: Medical news agency, 2009 (in Russian)
3. Geng X, Biancone L, Dai HH, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114:912-22. DOI:10.1016/s0016-5085(98)70310-5
4. Biancone L, Mandal A, Yang H, et al. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology. 1995;109:3-12. DOI:10.1016/0016-5085(95)90263-5
5. Van Sommeren S, Janse M, Karjalainen J, et al. Extraintestinal manifestations and complications in inflammatory bowel disease: From shared genetics to shared biological pathways. Inflamm Bowel Dis. 2014;20:987-94. DOI:10.1097/MIB.0000000000000032
6. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227-36. DOI:10.3748/wjg.v11.i46.7227
7. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:307-27. DOI:10.1016/s0889-8553(01)00019-x
8. Mendes FD, Levy C, Enders FB, et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007;102:344-50. DOI:10.1111/j.1572-0241.2006.00947.x
9. Khat,kov IE, Parfenov AI, Kniazev OV, et al. Inflammatory diseases in the practice of a therapist and surgeon. Moscow, 2017; p. 70–2 (in Russian)
1 ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия;
2 ГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента» Департамента здравоохранения г. Москвы, Москва, Россия;
3 ФГБУ «Национальный медицинский исследовательский центр колопроктологии им. А.Н. Рыжих» Минздрава России, Москва, Россия
*a.kagramanova@mknc.ru
________________________________________________
Anna V. Kagramanova*1, Oleg V. Knyazev1–3, Dmitrii S. Kulakov1–3, Elena V. Vinnitskaya1, Iuliia G. Sandler1, Nadezhda A. Savenkova1, Galina V. Lukina1, Asfold I. Parfenov1
1 Loginov Moscow Clinical Scientific Center, Moscow, Russia;
2 Research Institute of Health Organization and Medical Management, Moscow, Russia;
3 Ryzhih National Medical Research Center of Coloproctology, Moscow, Russia
*a.kagramanova@mknc.ru